Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

First results of aponermin(Apo) improving teclistamab (tec)/talquetamab (tal) in patients (pts) with Relapsed/Refractory multiple myeloma (RRMM)

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuechen ZhangYZYanru ZhangMLMenghan Liu

Discussion

Loading...

Member takes

Overview

Phase 1 trial shows 100% overall response rate in patients with advanced multiple myeloma, indicating potential for improved outcomes.

Key Points

  • To assess the safety and efficacy of aponermin combined with teclistamab and talquetamab in patients with relapsed/refractory multiple myeloma.
  • Conducted a phase 1 trial enrolling patients with relapsed/refractory multiple myeloma following standard therapy.
  • Evaluated safety and recommended phase 2 regimen via investigator assessments and CTCAE grading.
  • Monitored treatment-emergent adverse events and response rates at recommended dose levels.
  • At recommended phase 2 regimen, overall response rate was 100% among evaluable patients.
  • Cytokine release syndrome was the most common adverse event, occurring in 83.3% without severe grades.
  • Median follow-up time was 2.5 months, with a notable response in high-risk populations.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e08fhttps://doi.org/10.1182/blood-2025-7576
View Full Paper
Ask AI
Bookmark
Share